Liana Fraenkel1, Elizabeth K Seng2, Meaghan Cunningham2, Kristin Mattocks2. 1. Department of Medicine, Yale University School of Medicine, Yale University, New Haven, Department of Medicine, VA Connecticut Health Care System, West Haven, CT, Department of Psychology, Yeshiva University, New York, NY and Department of Research, VA Central Western Massachusetts, North Hampton, MA, USA. Department of Medicine, Yale University School of Medicine, Yale University, New Haven, Department of Medicine, VA Connecticut Health Care System, West Haven, CT, Department of Psychology, Yeshiva University, New York, NY and Department of Research, VA Central Western Massachusetts, North Hampton, MA, USA. liana.fraenkel@yale.edu. 2. Department of Medicine, Yale University School of Medicine, Yale University, New Haven, Department of Medicine, VA Connecticut Health Care System, West Haven, CT, Department of Psychology, Yeshiva University, New York, NY and Department of Research, VA Central Western Massachusetts, North Hampton, MA, USA.
Abstract
OBJECTIVE: We performed a qualitative study to better understand how patients with RA approach risk-benefit trade-offs inherent in the choice of remaining with their current treatment vs escalating care. METHODS: We used a think-aloud protocol to examine how patients with RA approach risk-benefit trade-offs inherent in the choice of remaining with their current treatment vs adding a biologic. The data emerging from the protocols were used to develop a conceptual model describing how patients approach the decision to escalate care. RESULTS: Participants who were strongly impacted by their disease were not open to considering alternative options. For some patients, being highly impacted by their disease results in a strong preference to escalate care. For others, the same level of distress is reason to unconditionally refuse additional medications. In contrast, those who were moderately impacted were more open to consider treatment options. Among these participants, however, subjects' risk-benefit trade-offs were consistently modified by factors unrelated to medication, including sociodemographic characteristics, role responsibilities and the quality of the patient-physician relationship. CONCLUSION: The conceptual model indicates that patients approach the decision to escalate care differently from physicians. In order to improve care in RA, it is important to recognize that many patients with moderate to high disease activity are not open to alternative treatments, which is a prerequisite to engaging in decision making. Routine clinical encounters should enable health care providers to identify these patients in order to tailor education prior to recommending treatment escalation.
OBJECTIVE: We performed a qualitative study to better understand how patients with RA approach risk-benefit trade-offs inherent in the choice of remaining with their current treatment vs escalating care. METHODS: We used a think-aloud protocol to examine how patients with RA approach risk-benefit trade-offs inherent in the choice of remaining with their current treatment vs adding a biologic. The data emerging from the protocols were used to develop a conceptual model describing how patients approach the decision to escalate care. RESULTS:Participants who were strongly impacted by their disease were not open to considering alternative options. For some patients, being highly impacted by their disease results in a strong preference to escalate care. For others, the same level of distress is reason to unconditionally refuse additional medications. In contrast, those who were moderately impacted were more open to consider treatment options. Among these participants, however, subjects' risk-benefit trade-offs were consistently modified by factors unrelated to medication, including sociodemographic characteristics, role responsibilities and the quality of the patient-physician relationship. CONCLUSION: The conceptual model indicates that patients approach the decision to escalate care differently from physicians. In order to improve care in RA, it is important to recognize that many patients with moderate to high disease activity are not open to alternative treatments, which is a prerequisite to engaging in decision making. Routine clinical encounters should enable health care providers to identify these patients in order to tailor education prior to recommending treatment escalation.
Authors: Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: Nasim A Khan; Horace J Spencer; Esam Abda; Amita Aggarwal; Rieke Alten; Codrina Ancuta; Daina Andersone; Martin Bergman; Jurgen Craig-Muller; Jacqueline Detert; Lia Georgescu; Laure Gossec; Hisham Hamoud; Johannes W G Jacobs; Ieda Maria Magalhaes Laurindo; Maria Majdan; Antonio Naranjo; Sapan Pandya; Christof Pohl; Georg Schett; Zahraa I Selim; Sergio Toloza; Hisahi Yamanaka; Tuulikki Sokka Journal: Arthritis Care Res (Hoboken) Date: 2012-02 Impact factor: 4.794
Authors: Richard Adair; Douglas R Wholey; Jon Christianson; Katie M White; Heather Britt; Suhna Lee Journal: Ann Intern Med Date: 2013-08-06 Impact factor: 25.391
Authors: Divya N V Challa; Zoran Kvrgic; Cynthia S Crowson; Eric L Matteson; Thomas G Mason; Clement J Michet; Daniel E Schaffer; Kerry A Wright; John M Davis Journal: Arthritis Care Res (Hoboken) Date: 2019-12-10 Impact factor: 4.794
Authors: Yomei Shaw; Ilinca D Metes; Kaleb Michaud; Julie M Donohue; Mark S Roberts; Marc C Levesque; Judy C Chang Journal: Arthritis Care Res (Hoboken) Date: 2018-03-11 Impact factor: 4.794
Authors: Justin K Owensby; Lang Chen; Ronan O'Beirne; Eric M Ruderman; Leslie R Harrold; Joshua A Melnick; Monika M Safford; Jeffrey R Curtis; Maria I Danila Journal: Arthritis Care Res (Hoboken) Date: 2020-07 Impact factor: 4.794
Authors: Anthony M Louder; Amitabh Singh; Kim Saverno; Joseph C Cappelleri; Aaron J Aten; Andrew S Koenig; Margaret K Pasquale Journal: Am Health Drug Benefits Date: 2016-04
Authors: Ayano Kelly; Kathleen Tymms; David J Tunnicliffe; Daniel Sumpton; Chandima Perera; Kieran Fallon; Jonathan C Craig; Walter Abhayaratna; Allison Tong Journal: Arthritis Care Res (Hoboken) Date: 2018-03-24 Impact factor: 4.794